| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 10/25 | 02/27 | | |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
